On May 1, 2025, D. Boral Capital, under the analysis of Jason Kolbert, reaffirmed its "Buy" rating for Pulmonx (LUNG, Financial), maintaining the price target at USD 17.00. This decision reflects a steady outlook on the company's performance without any changes to the previous valuation.
According to the latest report, the price target for Pulmonx (LUNG, Financial) remains unchanged at USD 17.00, consistent with prior evaluations. The rating has also been maintained at a "Buy," indicating confidence in the stock's potential for growth.
The decision to maintain both the rating and price target was confirmed by D. Boral Capital, with no percentage change in the price target from previous assessments. Pulmonx (LUNG, Financial), listed on the NASDAQ exchange, continues to be highlighted as a promising investment option by the analyst, Jason Kolbert.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for Pulmonx Corp (LUNG, Financial) is $12.07 with a high estimate of $17.00 and a low estimate of $7.50. The average target implies an upside of 216.82% from the current price of $3.81. More detailed estimate data can be found on the Pulmonx Corp (LUNG) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, Pulmonx Corp's (LUNG, Financial) average brokerage recommendation is currently 2.1, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Pulmonx Corp (LUNG, Financial) in one year is $16.92, suggesting a upside of 344.07% from the current price of $3.8102. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Pulmonx Corp (LUNG) Summary page.
